By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is bearish on Bristol-Myers Squibb (BMY), with key concerns being the patent cliff in 2026 and 2028, high leverage due to recent acquisitions, and the risk of pipeline delays or failures. The high dividend payout ratio (70%) and potential margin compression due to interest expenses are also significant risks.
Risk: High leverage and pipeline execution uncertainty
Opportunity: None mentioned
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Bristol Myers Squibb's stock looks cheap on several key metrics.
The company has patent expirations that will be a headwind through 2028.
Bristol Myers Squibb (NYSE: BMY) is a well-respected pharmaceutical company. Technically, it was created in 1989 through the merger of two other companies, but both of those businesses were founded in the 1800s. It is a proven survivor that clearly knows how to navigate the highly complex and competitive drug industry. And the stock looks cheap today. But is it really as cheap as it looks?
Bristol Myers Squibb's price-to-earnings ratio is currently sitting around 16x. That's well below the S&P 500's (SNPINDEX: ^GSPC) 27x and the pharmaceutical industry's 24x average. Meanwhile, Bristol Myers Squibb's dividend yield is a highly attractive 4.4%. By comparison, the S&P 500 index has a yield of 1.1%, and the average drug maker's yield is around 1.7%.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
It would be understandable if value investors jumped aboard. For dividend investors attracted to the lofty yield, the company's 70% payout ratio is a bit high but not unreasonably so. Still, you should ask yourself why the company looks attractively priced before you buy it.
Bristol Myers Squibb isn't likely to go out of business anytime soon. If your investment horizon is decades long, you may want to own this stock today, given its attractive valuation metrics. However, you'll have to be prepared for some uncertainty through at least the end of 2028. That's because the company has key drugs with upcoming patent expirations. Revlimid and Pomalyst, both cancer drugs, will get hit in 2026, and cardiovascular drug Eliquis, which is marketed with competitor Pfizer (NYSE: PFE), is set to face generic competition in 2028.
To be fair, the company has been working on its drug pipeline. But research and development don't work on a timeline, while patent expirations do. There could be a timing mismatch that leaves Bristol Myers Squibb's top and bottom lines under material pressure in the near term. So, the stock looks like it is a bargain, but there's a reason for the discounted price.
The pharmaceutical business is intensely competitive. Bristol Myers Squibb has proven it knows how to survive in the long term, and the price has some value and income appeal today. However, it may not be as cheap as it seems when you factor in near-term patent headwinds. If you are hoping to make a quick buck, you should probably look elsewhere.
That said, if your plan is to hold the stock for decades, Bristol Myers Squibb may still be worth buying. After all, it is probably better to buy a good company at an attractive price than to try to time the bottom with every purchase, which is a virtually impossible task to do consistently.
Before you buy stock in Bristol Myers Squibb, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bristol Myers Squibb wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $463,900! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,294,401!
Now, it’s worth noting Stock Advisor’s total average return is 978% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of June 1, 2026. *
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb and Pfizer. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"BMY's valuation discount is justified by patent cliffs through 2028, but the bull case hinges entirely on pipeline strength—which the article never quantifies."
The article frames BMY as a value trap—cheap on metrics but justifiably so due to patent cliffs (Revlimid/Pomalyst 2026, Eliquis 2028). The 16x P/E vs. 24x pharma average and 4.4% yield do look attractive, but here's what's underexamined: BMY's pipeline maturity. The article waves at 'working on drug pipeline' without specifics. If BMY has 2-3 late-stage assets with blockbuster potential launching 2025-2027, the patent cliff becomes a non-event—you're buying a company transitioning, not declining. The 70% payout ratio also matters: if cash flow deteriorates post-2026, dividend safety becomes the real risk, not valuation. The article conflates 'cheap' with 'bad timing,' but timing arbitrage exists if pipeline visibility is strong.
If BMY's pipeline is genuinely thin and patent losses exceed new launch revenue by $3-5B annually, the stock could re-rate to 12-13x P/E, making today's 16x still expensive despite the yield lure.
"BMY's valuation already discounts the patent cliffs assuming only moderate pipeline offsets, creating an attractive entry for holders through 2030."
The article rightly flags BMY's 2026 Revlimid/Pomalyst and 2028 Eliquis patent cliffs as revenue risks, but it understates how quickly the company's $50B+ in recent acquisitions (KarXT, RayzeBio, etc.) and late-stage oncology/hematology assets could offset losses. At 16x forward earnings and 4.4% yield versus sector 24x/1.7%, the discount already embeds partial cliff impact; any pipeline beat would drive re-rating. Near-term EPS pressure through 2027 is likely, yet the long-term survivor narrative holds if R&D timelines align even modestly with expirations.
If the acquired assets face regulatory delays or weaker-than-expected uptake, the 70% payout ratio leaves little cushion and a dividend cut becomes probable well before 2028.
"BMY is not a bargain but a value trap, as the market is correctly discounting the stock for the significant revenue gap created by the upcoming patent cliff."
The market is pricing BMY at a 16x P/E because it correctly identifies a 'patent cliff' as a terminal value risk, not just a temporary headwind. While the 4.4% yield is enticing, the 70% payout ratio leaves little margin for error if the R&D pipeline fails to deliver blockbusters to replace Eliquis and Revlimid revenue. The article misses the critical point of capital allocation: BMY has been aggressively acquiring smaller biotechs (e.g., Karuna Therapeutics) to plug growth gaps, which inflates debt and risks overpaying for unproven assets. Until we see clinical success from these recent acquisitions, the stock is a value trap that will likely trade sideways until 2028.
If BMY’s recent M&A strategy successfully pivots their portfolio toward high-growth neuroscience and immunology, the current valuation will look like a generational entry point once the market stops obsessing over legacy patent expirations.
"BMY looks cheap only if you ignore looming patent expirations and potential near-term earnings pressure that could erode dividend coverage and compress the multiple before any pipeline payoff materializes."
The article touts BMY as cheap (~16x earnings, 4.4% yield vs. ~1.1% for the S&P), but it glosses over a near-term revenue cliff: Revlimid and Pomalyst patent expirations in 2026 and Eliquis generic competition in 2028. Even with a diverse pipeline, the timing risk is real and could pressure top-line growth and free cash flow, challenging dividend sustainability given a ~70% payout ratio. Valuation hinges on long-horizon assumptions about pipeline success and delayed earnings impact; if near-term earnings miss or slower-than-expected approvals occur, multiple compression could occur before any meaningful upside from new launches.
Bull case: even with patent cliffs, Eliquis’ entrenched market position and potential near-term pipeline upside could sustain high cash flow, supporting a re-rating if approvals and launches materialize faster than feared.
"Nobody's stress-tested the debt-to-FCF math if pipeline delays compound with patent cliff revenue loss simultaneously."
Gemini flags M&A overpayment risk, but nobody's quantified the actual debt burden post-acquisitions. BMY's net debt-to-EBITDA matters here: if it's >3x and FCF declines 15-20% post-2026, dividend sustainability flips from 'manageable' to 'cut-likely' fast. Claude and Grok both assume pipeline success offsets cliffs, but that's priced in at 16x already. The real question: what's the probability-weighted NPV of BMY's late-stage assets, and does it justify holding through 2027 earnings volatility?
"BMY's acquisition debt collides with patent cliffs in a way that amplifies dividend and leverage risk beyond what valuation discussions have addressed."
Claude's net debt-to-EBITDA threshold misses the timing mismatch: the $50B acquisitions were funded by peak Eliquis/Revlimid cash flows that roll off exactly as integration and interest expenses rise. This sequencing means even modest pipeline delays could push leverage above 3.5x while FCF drops, turning the 70% payout into an immediate cut candidate rather than a 2028 problem. The 16x multiple embeds none of this overlap risk.
"Rising refinancing costs on debt-funded acquisitions will compress margins and threaten the dividend regardless of pipeline success."
Grok correctly identifies the leverage trap, but you are all ignoring the cost of capital. BMY’s M&A spree occurred during a low-rate environment. With net debt-to-EBITDA rising, refinancing costs will cannibalize the very FCF needed to support the dividend. Even if the pipeline succeeds, the interest expense drag on EPS will prevent the multiple expansion you’re hoping for. This isn't just a patent cliff; it’s a structural margin compression story that makes the 4.4% yield a yield-trap.
"Front-loaded refinancing risk could threaten BMY's dividend safety by 2025–2026 long before the 2028 patent cliff materializes, due to M&A debt and rising rates."
Grok's leverage worry is fair, but it misses front-loaded refinancing risk from the M&A binge. With rate shocks, near-term debt maturities, integration costs, and higher interest costs, net leverage above 3x could press FCF and dividend coverage by 2025–2026, long before 2028. The real risk isn't a late patent cliff; it's whether cash flow can sustain the 70% payout as leverage tightens and pipeline execution remains a wild card.
The panel consensus is bearish on Bristol-Myers Squibb (BMY), with key concerns being the patent cliff in 2026 and 2028, high leverage due to recent acquisitions, and the risk of pipeline delays or failures. The high dividend payout ratio (70%) and potential margin compression due to interest expenses are also significant risks.
None mentioned
High leverage and pipeline execution uncertainty